VivoSeq
Other

FSHD

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

FSHD is an early-stage landscape with 0 programs across 1 company. The most active players are Avidity Biosciences, Inc..

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avidity Biosciences, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

3

clinical trials

Recruiting2 · 67%
Completed1 · 33%

Clinical Trials

Trial Activity

Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2
Completed·—·N/A·NCT01970735·103 enrolled
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Recruiting·AAvidity Biosciences, Inc.·Phase 3·NCT07038200·200 enrolled
Clenbuterol to Target DUX4 in FSHD
Recruiting·—·Phase 1·NCT06721299·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)